| Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction M Stahl, MK Walz, M Stuschke, N Lehmann, HJ Meyer, ... Journal of clinical oncology 27 (6), 851-856, 2009 | 1245 | 2009 |
| NASH limits anti-tumour surveillance in immunotherapy-treated HCC D Pfister, NG Núñez, R Pinyol, O Govaere, M Pinter, M Szydlowska, ... Nature 592 (7854), 450-456, 2021 | 982 | 2021 |
| Swarm learning for decentralized and confidential clinical machine learning S Warnat-Herresthal, H Schultze, KL Shastry, S Manamohan, ... Nature 594 (7862), 265-270, 2021 | 758 | 2021 |
| Natural killer cell–mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate S Armeanu, M Bitzer, UM Lauer, S Venturelli, A Pathil, M Krusch, S Kaiser, ... Cancer research 65 (14), 6321-6329, 2005 | 454 | 2005 |
| Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre … M Javle, S Roychowdhury, RK Kelley, S Sadeghi, T Macarulla, KH Weiss, ... The Lancet Gastroenterology & Hepatology 6 (10), 803-815, 2021 | 358 | 2021 |
| Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial M Stahl, MK Walz, J Riera-Knorrenschild, M Stuschke, A Sandermann, ... European Journal of Cancer 81, 183-190, 2017 | 284 | 2017 |
| NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer C Heining, P Horak, S Uhrig, PL Codo, B Klink, B Hutter, M Fröhlich, ... Cancer discovery 8 (9), 1087-1095, 2018 | 241 | 2018 |
| Early IFN-α signatures and persistent dysfunction are distinguishing features of NK cells in severe COVID-19 B Krämer, R Knoll, L Bonaguro, M ToVinh, J Raabe, ... Immunity 54 (11), 2650-2669. e14, 2021 | 211 | 2021 |
| Antibody-induced procoagulant platelets in severe COVID-19 infection K Althaus, I Marini, J Zlamal, L Pelzl, A Singh, H Häberle, M Mehrländer, ... Blood, The Journal of the American Society of Hematology 137 (8), 1061-1071, 2021 | 206 | 2021 |
| Prognosis of patients with hepatocellular carcinoma treated with immunotherapy–development and validation of the CRAFITY score B Scheiner, K Pomej, MM Kirstein, F Hucke, F Finkelmeier, O Waidmann, ... Journal of hepatology 76 (2), 353-363, 2022 | 205 | 2022 |
| Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers P Horak, C Heining, S Kreutzfeldt, B Hutter, A Mock, J Hüllein, M Fröhlich, ... Cancer discovery 11 (11), 2780-2795, 2021 | 204 | 2021 |
| Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial JM Llovet, M Kudo, P Merle, T Meyer, S Qin, M Ikeda, R Xu, J Edeline, ... The lancet oncology 24 (12), 1399-1410, 2023 | 202 | 2023 |
| The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation H Bösmüller, S Traxler, M Bitzer, H Häberle, W Raiser, D Nann, ... Virchows Archiv 477, 349-357, 2020 | 194 | 2020 |
| Resveratrol as a pan-HDAC inhibitor alters the acetylation status of jistone proteins in human-derived hepatoblastoma cells S Venturelli, A Berger, A Böcker, C Busch, T Weiland, S Noor, ... PloS one 8 (8), e73097, 2013 | 181 | 2013 |
| HDAC inhibitor treatment of hepatoma cells induces both TRAIL‐independent apoptosis and restoration of sensitivity to TRAIL A Pathil, S Armeanu, S Venturelli, P Mascagni, TS Weiss, M Gregor, ... Hepatology 43 (3), 425-434, 2006 | 152 | 2006 |
| Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357 S Armeanu, A Pathil, S Venturelli, P Mascagni, TS Weiss, M Göttlicher, ... Journal of hepatology 42 (2), 210-217, 2005 | 151 | 2005 |
| Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma–the SHELTER study M Bitzer, M Horger, EG Giannini, TM Ganten, MA Wörns, JT Siveke, ... Journal of hepatology 65 (2), 280-288, 2016 | 145 | 2016 |
| Direct and natural killer cell-mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma S Armeanu, M Krusch, KM Baltz, TS Weiss, I Smirnow, A Steinle, ... Clinical cancer research 14 (11), 3520-3528, 2008 | 124 | 2008 |
| Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinoma S Venturelli, S Armeanu, A Pathil, CJ Hsieh, TS Weiss, R Vonthein, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2007 | 124 | 2007 |
| Kaempferol, a new nutrition-derived pan-inhibitor of human histone deacetylases A Berger, S Venturelli, M Kallnischkies, A Böcker, C Busch, T Weiland, ... The Journal of Nutritional Biochemistry 24 (6), 977-985, 2013 | 123 | 2013 |
